Condition: Acute Myeloid Leukemia (AML) · Sponsor: Stephan Grupp MD PhD
This study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult subjects with relapsed or refractory AML. Subjects will be enrolled into one of two treatment cohorts: subjects who will receive CART123 alone (Cohort A) or subjects who will receive CART123 in combination with ruxolitinib (Cohort B).
This description comes directly from the study's public registry record.
Cell Therapy Nurse Navigator · 445-942-5891 · CARTNurseNavigator@chop.edu
Melissa Varghese · varghesem@chop.edu
Always discuss trial participation with your own doctor first.
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07464951